Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Non-Current Assets (2019 - 2026)

Alx Oncology Holdings' Non-Current Assets history spans 5 years, with the latest figure at $53.9 million for Q4 2023.

  • On a quarterly basis, Non-Current Assets rose 51.73% to $53.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $146.9 million, a 9.86% increase, with the full-year FY2023 number at $53.9 million, up 51.73% from a year prior.
  • Non-Current Assets hit $53.9 million in Q4 2023 for Alx Oncology Holdings, up from $21.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ALXO hit a ceiling of $53.9 million in Q4 2023 and a floor of $45000.0 in Q3 2020.
  • Historically, Non-Current Assets has averaged $19.8 million across 5 years, with a median of $17.1 million in 2021.
  • Biggest five-year swings in Non-Current Assets: tumbled 92.85% in 2020 and later skyrocketed 23822.22% in 2021.
  • Tracing ALXO's Non-Current Assets over 5 years: stood at $867000.0 in 2019, then plummeted by 92.85% to $62000.0 in 2020, then skyrocketed by 21132.26% to $13.2 million in 2021, then surged by 169.83% to $35.5 million in 2022, then surged by 51.73% to $53.9 million in 2023.
  • Business Quant data shows Non-Current Assets for ALXO at $53.9 million in Q4 2023, $21.0 million in Q3 2023, and $26.4 million in Q2 2023.